Anticipated classes of new medications and molecular targets for pulmonary arterial hypertension.
Morrell NW, Archer SL, Defelice A, Evans S, Fiszman M, Martin T, Saulnier M, Rabinovitch M, Schermuly R, Stewart D, et al. Pulm Circ. 2013 Jan; 3(1):226-44.